Lorcaserin maintenance fails to attenuate heroin vs. food choice in rhesus monkeys

E. Andrew Townsend[a], S. Stevens Negus[a], Justin L. Poklis[a], Matthew L. Banks[a,✉]

[a] Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298 USA

✉ Corresponding Author:

Matthew L. Banks, PharmD, PhD

E: matthew.banks@vcuhealth.org

410 North 12th St, Box 980613

Richmond, VA 23298, USA

Abstract

Background: The current opioid crisis has reinvigorated preclinical research in the evaluation of non-opioid candidate treatments for opioid use disorder (OUD). Emerging evidence suggests 5-HT_{2C} receptor agonists may attenuate the abuse-related effects of opioids. This study evaluated effectiveness of repeated 7-day treatment with the 5-HT_{2C} agonist lorcaserin on heroin-vs.-food choice in rhesus monkeys. Lorcaserin effects were compared to effects produced by saline substitution and by treatment with the opioid antagonist naltrexone.

Methods: Adult male (1) and female (6) rhesus monkeys were trained to respond under a concurrent schedule of food delivery (1g pellets, fixed-ratio 100 schedule) and intravenous heroin injections (0-0.032 mg/kg/injection, fixed-ratio 10 schedule) during daily 2h sessions. Heroin choice dose-effect functions were determined daily before and following 7-day saline substitution or 7-day continuous treatment with naltrexone (0.0032-0.032 mg/kg/h, IV) or lorcaserin (0.032-0.32 mg/kg/h, IV).

Results: Under baseline conditions, increasing heroin doses maintained a dose-dependent increase in heroin choice. Both saline substitution and 7-day naltrexone treatment significantly attenuated heroin choice and produced a reciprocal increase in food choice. Continuous lorcaserin treatment significantly increased heroin choice.

Conclusions: In contrast to saline substitution and naltrexone maintenance, lorcaserin maintenance was ineffective to reduce heroin-vs.-food choice. These preclinical results do not support the therapeutic potential of lorcaserin as a candidate OUD treatment.

Keywords: Lorcaserin, naltrexone, heroin, choice, rhesus monkeys, females

1.0 Introduction

Despite the availability of methadone, buprenorphine, and naltrexone as Food and Drug Administration (FDA)-approved pharmacotherapies for opioid use disorder (OUD) in the United States, the opioid crisis remains a significant public health issue. One reason for the ongoing opioid crisis is that the majority of patients who meet diagnostic criteria for OUD do not seek medical help (Blanco et al., 2013; Han et al., 2018). Other reasons include poor treatment adherence (especially for naltrexone), barriers to treatment access (especially for methadone), and abuse-liability concerns (for methadone and buprenorphine) (Blanco and Volkow, 2019; Volkow et al., 2014). Furthermore, a proportion of patients who do receive treatment will still relapse, highlighting the clinical need for other OUD monotherapies or adjuncts to existing FDA-approved treatments (Lee et al., 2018). In response to the opioid crisis, the National Institutes of Health have outlined several strategies to focus scientific efforts culminating in the "Helping to End Addiction Long-Term" (HEAL) initiative (Collins et al., 2018; Volkow and Collins, 2017). One prioritized area for preclinical research is the development and evaluation of novel OUD medications.

The abuse-related effects of mu opioid receptor (MOR) agonists are thought to be mediated at least in part by activation of mesolimbic dopamine (DA) neurons that originate in the ventral tegmental area and project to forebrain regions such as the nucleus accumbens (Koob and Volkow, 2016). More specifically, mesolimbic DA neurons receive inhibitory inputs from GABA-ergic interneurons that express $G_{i/o}$-protein-coupled MORs, and MOR agonist binding to these receptors inhibits GABA neuron activity to disinhibit and activate downstream mesolimbic DA neurons. These GABA-ergic neurons also express excitatory G_q/G_{11}-protein-coupled 5-HT_{2C} receptors (Hannon and Hoyer, 2008), and 5-HT_{2C} agonists have the potential to oppose and limit MOR agonist effects on activity of both GABA-ergic neurons and downstream mesolimbic DA neurons. For example, acute pretreatment with the 5-HT_{2C} receptor agonist MK-212 blunted morphine-induced increases in nucleus accumbens extracellular DA levels (Willins and Meltzer, 1998). Consistent with this neurochemical evidence, acute pretreatment with the 5-HT_{2C} receptor agonist lorcaserin decreased reinstatement of operant-responding previously

maintained by remifentanil in rhesus monkeys (Maguire et al., 2019) or by oxycodone in rats (Neelakantan et al., 2017). Acute lorcaserin pretreatment also decreased oxycodone self-administration in rats (Neelakantan et al., 2017) and heroin self-administration in rhesus monkeys (Kohut and Bergman, 2018). Furthermore, lorcaserin treatment effects were both sustained during repeated lorcaserin administration and selective for heroin vs. food-maintained responding in rhesus monkeys (Kohut and Bergman, 2018). On the basis of these and related findings, the 5-HT_{2C} receptor has emerged as a pharmacological target of interest by the National Institute on Drug Abuse to address the opioid crisis (Rasmussen et al., 2019; Volkow and Collins, 2017).

To further evaluate 5-HT_{2C} agonists as candidate treatments for OUD, the present study evaluated lorcaserin effectiveness to reduce intravenous (IV) heroin self-administration under a heroin-vs.-food choice procedure in rhesus monkeys. A preclinical heroin-vs.-food choice procedure was utilized for two reasons. First, although 5-HT_{2C} agonists can selectively reduce opioid self-administration more than food-maintained responding under some conditions, the magnitude of this selectivity appears to be modest (≤3-fold), and lorcaserin is clearly effective to decrease rates of food-maintained responding at doses similar to or only slightly higher than those that decrease rates of opioid self-administration (e.g. Banks and Negus, 2017). Drug-vs.-food choice procedures provide an alternative strategy to dissociate selective treatment effects on opioid reinforcement (evaluated as changes in behavioral allocation between drug and food choice) from non-selective treatment effects on operant responding (evaluated as changes in overall behavioral rates maintained by either drug or food choice) (Griffiths et al., 1976; Johanson, 1976; Woolverton and Balster, 1979; Hart et al., 2000; Negus, 2006) Second, these procedures have increasingly demonstrated translational concordance with both human laboratory studies and clinical trials across a broad range of abused drug classes, including opioids (for review, see (Banks, 2017; Banks et al., 2015; Banks and Negus, 2017; Negus and Banks, 2013)). To provide a framework for interpreting lorcaserin effects, the effects of two other manipulations were examined. First, saline was substituted for heroin for seven consecutive days to examine extinction of heroin choice when heroin was absent. Second, monkeys were treated continuously for seven consecutive days with each of three different doses

of naltrexone (0.0032-0.032 mg/kg/h). Naltrexone served as a positive control because depot naltrexone formulations are FDA-approved for OUD treatment in non-dependent patients (Comer et al., 2006; Krupitsky et al., 2011; Tanum et al., 2017). Human laboratory studies suggest that clinically effective depot naltrexone reduces opioid potency at least 8-fold (Sullivan et al., 2006), and any candidate OUD treatment should be at least as effective as these FDA-approved naltrexone formulations to warrant further consideration.

2.0 Methods

2.1 Subjects: Studies were conducted in a total of seven adult rhesus monkeys (*Macaca mulatta*) of Indian origin (one male, six females). Monkeys were surgically implanted with a double-lumen venous catheter (extruded silicone i.d. = 0.76 mm, o.d. = 2.36 mm, durometer = 60; Reiss Manufacturing, Blackstone, VA) for studies of heroin-vs.-food choice. Three female monkeys had prior opioid drug discrimination histories, the male monkey had prior cocaine self-administration history, and the other three female monkeys were experimentally naïve. Monkeys could earn 1-g banana-flavored pellets (5TUR Grain-based Precision Primate Tablets; Test Diets, Richmond, IL) during daily experimental sessions (see below). The monkeys' diet consisted of food biscuits (Teklad Global Diet, 2050, 20% Protein Primate Diet) and fresh fruit or vegetables delivered in the afternoons after behavioral sessions to minimize the effects of biscuit availability and consumption on food-maintained operant responding. Water was continuously available in each monkey's home chamber, which also served as the experimental chamber. A 12-h light/dark cycle was in effect (lights on from 0600 to 1800 h). Environmental enrichment consisting of movies displayed on a monitor in the housing room and foraging devices loaded with nuts, seeds, or diced vegetables, was also provided after behavioral sessions. Facilities were licensed by the United States Department of Agriculture and accredited by the AAALAC International. The Institutional Animal Care and Use Committee approved all experimental and enrichment protocols. Animal research and husbandry were conducted according to the 8th edition of the Guide for the Care and Use of Laboratory Animals.

2.2 Heroin vs. food choice procedure: Each housing chamber was equipped with a customized operant response panel, which had two response keys that could be transilluminated red or yellow, and a pellet dispenser (Med Associates, ENV-203–1000, St. Albans, VT) that delivered food pellets to a receptacle below the operant panel. The externalized portion of the intravenous (IV) catheter was routed through a custom jacket and tether system connected to a dual-channel fluid swivel (Lomir Biomedical, Malone, NY) on the chamber top and connected to two safety syringe pumps (Med Associates, PHM-108), one for each lumen of the double-lumen catheter. One pump (the "self-administration" pump) was used to deliver contingent IV heroin or saline injections through one lumen of the double-lumen catheter. The second pump (the "treatment" pump) was used to deliver non-contingent IV saline, naltrexone (0.0032-0.032 mg/kg/h), or lorcaserin (0.032-0.32 mg/kg/h) injections through the second lumen at a programmed rate of 0.1 mL injections every 20 min from 1200 h each day until 1100 h the next morning. Catheter patency was periodically evaluated with IV ketamine (Vedco, St. Joseph, MO) administration and after any treatment that produced a rightward shift in the heroin choice dose-effect function. The catheter was considered patent if IV ketamine administration produced muscle tone loss within 10 s.

Daily experimental sessions were conducted from 0900 to 1100 h in each monkey's home chamber as described previously for heroin-, cocaine-, and methamphetamine-vs.-food choice studies (Banks and Blough, 2015; Banks et al., 2011; Negus, 2006). The terminal choice schedule consisted of five 20-min components separated by 5-min inter-component intervals during which responding had no scheduled consequences. During each component, the left, food-associated key was transilluminated red, and completion of the FR requirement (FR100) resulted in food pellet delivery. In addition, the right, heroin-associated key was transilluminated yellow, and completion of the FR requirement (FR10) resulted in delivery of the unit heroin dose available during that component. The unit heroin doses available during each of the five successive components were 0, 0.001, 0.0032, 0.01, and 0.032mg/kg/injection, respectively, and dose was varied by changing the resulting volume (0. 0.03, 0.1, 0.3, and 1.0 ml/injection, respectively) of each injection. Stimulus lights on the heroin-associated key

were flashed on and off in 3 s cycles, and longer flashes were associated with larger heroin doses. Ratio requirement completion initiated a 3 s timeout, during which all stimulus lights were turned off, and responding had no scheduled consequences. Choice behavior was considered to be stable when the lowest unit heroin dose maintaining at least 80% heroin choice varied by ≤0.5 log units for three consecutive days. Data from these three days were subsequently used as the "baseline" for statistical and graphical comparisons to each treatment.

Once heroin-vs.-food choice was stable, experimental test periods were conducted to determine effects of saline substitution and of treatment with naltrexone or lorcaserin on heroin-vs.-food choice. For saline substitution, saline replaced heroin in the self-administration pump for seven consecutive days and saline continued to be infused via the treatment pump. For naltrexone and lorcaserin treatments, heroin was retained in the self-administration pump, naltrexone or lorcaserin solutions replaced saline in the treatment pump, and each naltrexone (0.0032-0.032 mg/kg/h, IV) and lorcaserin (0.032-0.32 mg/kg/h, IV) dose was tested for seven consecutive days. At the conclusion of each 7-day saline-substitution or drug-treatment test period, heroin and saline solutions were reinstated as necessary in the self-administration and treatment pumps, respectively, and responding was monitored for at least 4 days and until heroin-vs.-food choice had returned to pretest levels. Each treatment was evaluated in at least four monkeys. Saline substitution was evaluated in all monkeys before drug treatments, and five monkeys received both naltrexone and lorcaserin. The dose order within each drug was counterbalanced across subjects, and in those monkeys that received both naltrexone and lorcaserin, naltrexone was tested first.

2.3 Naltrexone and lorcaserin plasma sample analysis: Blood was collected from monkeys under ketamine anesthesia at day seven during continuous naltrexone or lorcaserin treatment into vacutainer tubes. Tubes were immediately centrifuged at 1000g for 10 min, and the plasma supernatant was transferred into a storage tube and frozen at –80°C until analyzed. A seven-point calibration curve (naltrexone: 1-500 ng/mL, lorcaserin 10-1000 ng/ml) was determined, which included a drug-free control

and a negative control without internal standard (ISTD) in drug-free plasma. Naltrexone was extracted from the plasma using a liquid/liquid extraction. In brief, 100 ng/mL naltrexone-d_3 and the ISTDs were added to 100 µL aliquots of plasma of each calibrator, control, or specimen except the negative control. Next, 0.5 mL of saturated carbonate/ bicarbonate buffer (1:1, pH 9.5) and 1.0 mL of chloroform:2-propanol (9:1) were added. Naltrexone samples were mixed for 5 min and centrifuged at 2500 rpm for 5 min. The top aqueous layer was aspirated, and the organic layer was transferred to a clean test tube and evaporated to dryness at 40°C under a constant stream nitrogen. The samples were reconstituted with methanol and placed in auto-sampler vials for analysis. Lorcaserin was extracted from the plasma using the addition of acetonitrile. In brief, the ISTD, 10 ng of cocaine-d3, was added to aliquots of 100 µL of the calibrators, controls and samples. These samples were mixed and allowed to equilibrate. 0.2 mL acetonitrile was added to each sample and vortex mixed. The samples were then centrifuged at 2054 g for 10 min. After centrifuging the top layer containing the acetonitrile was removed and placed in auto-sampler vials for analysis.

The ultra-performance liquid chromatography tandem mass spectrometer (UPLC-MS/MS) analysis was performed for naltrexone and lorcaserin on a Sciex 6500 QTRAP system with an IonDrive Turbo V source for TurbolonSpray® (Sciex, Ontario, Canada) attached to a Shimadzu UPLC system (Kyoto, Japan) controlled by Analyst software (Sciex, Ontario, Canada). Chromatographic separation of naltrexone was performed using a Zorbax XDB-C18 4.6 x 75 mm, 3.5-micron column (Agilent Technologies, Santa Clara, CA). The mobile phase contained water:methanol (80:20, v/v) with 1 g/L ammonium formate and 0.1 % formic acid and was delivered at a flow rate of 1 mL/min. The source temperature was set at 650°C. Curtain gas flow rate was set to 30 mL/min. The ionspray voltage was 5500 V, with the ion source gases 1 and 2 having flow rates of 60 mL/min. The declustering potential and collection energy were 86 eV and 39 eV, respectively. The quantification and qualifying transition ions were monitored in positive multiple reaction monitoring mode: Naltrexone 342> 267 and 342 > 282 and Naltrexone-d_3 345> 270 and 345 > 285. For lorcaserin, chromatographic separation of lorcaserin and the ISTD, cocaine-d3, was performed using a Thermo Hypersil Gold column, 50 x 2.1 mm, 3 micron

(Thermofisher Scientific, USA). The mobile phase contained water/methanol (40:60, v/v) with 0.1 mM ammonium formate and was delivered at a flow rate of 1 mL/min. The source temperature was set at 600°C, and curtain gas had a flow rate of 30 mL/min. The ionspray voltage was 5500 V, with the ion source gases 1 and 2 having flow rates of 60 and 45 mL/min, respectively. The declustering potential and collection energy were for lorcaserin and the ISTD were 100 and 38 V, respectively. The acquisition mode used was multiple reaction monitoring. The following transition ions (m/z) with their corresponding collision energy in parentheses were monitored in negative mode for lorcaserin: 196>144 (34) and 196>129 (40) and in positive mode for cocaine-d3: 307>185 (28) and 307>105 (50). The total run time for the analytical method was 4 min. A linear regression of the peak area of ratios of the quantification transition ions and the ISTDs transition ions were used to construct the calibration curves.

2.4 Data analysis: Two primary dependent measures were determined for each component: (1) percent heroin choice, defined as (number of ratio requirements, or 'choices,' completed on the heroin-associated key/total number of ratio requirements completed on both the heroin- and food-associated keys)*100, and (2) the number of choices completed per component. Mean data from the three days preceding each pharmacological treatment were averaged for each individual monkey and then averaged across monkeys to yield group mean "baseline" data. Mean data from the last 3 days of each 7-day naltrexone or lorcaserin were averaged for each individual monkey and then averaged across monkeys to yield group mean data. Percent heroin choice and number of choices completed per component were then plotted as a function of the unit heroin dose and analyzed using a repeated-measures two-way ANOVA (saline substitution, naltrexone) or mixed-effects analysis (lorcaserin) with treatment drug dose and unit heroin dose as the fixed main effects (Prism 8.0.1 for macOS, GraphPad Software, San Diego, CA). Additional dependent measures collected during each session were total choices, total food choices, and total heroin choices. These dependent measures were also analyzed using a repeated-measures two-way ANOVA (naltrexone) or mixed-effects analysis (lorcaserin) with treatment drug dose and dependent measure as the fixed main effects. Following a significant interaction, a Dunnett's test was performed to compare

treatment effects to baseline within a unit heroin dose or session dependent measure. Following a significant effect of treatment in the absence of an interaction, a Dunnett's test was performed to compare collapsed treatment effects to baseline, irrespective of unit heroin dose or session dependent measure. The criterion for significance was set *a priori* at the 95% confidence level ($p<0.05$).

2.4 Drugs: Heroin HCl and (-)-naltrexone HCl were provided by the National Institute on Drug Abuse Drug Supply Program (Bethesda, MD) and dissolved in sterile saline. Lorcaserin HCl was purchased from a commercial supplier (MedChem Express, Monmouth Junction, NJ) and dissolved in sterile water. Heroin, naltrexone, and lorcaserin solutions were passed through a 0.22-micron sterile filter (Millex GV, Millipore Sigma, Burlington, MA) before administration. All drug doses were expressed as the salt forms listed above and delivered mg/kg based on weights collected bi-weekly to monthly.

3.0 Results

3.1 Baseline heroin vs. food choice and effect of saline substitution

Under baseline conditions, monkeys primarily chose food over heroin when heroin was not available (0 mg/kg/injection) or the unit heroin dose was small (0.001 mg/kg/injection) and almost exclusively reallocated their behavior to heroin choice during availability of larger unit heroin doses (0.01-0.032 mg/kg/injection) (**Figures 1A, 2A, 3A**; dashed lines). In addition, monkeys generally completed each of the ten possible ratio requirements of each component, although rate-decreasing effects of 0.032 mg/kg/injection heroin were observed (**Figures 1B, 2C, 3C**; dashed lines). **Figure 1** shows the average of the last three days of a 7-day saline substitution for heroin on percent choice (A) and the number of choices completed per component (B). Saline substitution resulted in a significant behavioral reallocation away from previously reinforced heroin-associated key and associated discriminative stimuli towards the food-associated key during components associated with previous 0.0032-0.032 mg/kg/injection heroin availability (**Figure 1A**: choice component: $F_{1.1,5.5} = 37.9$, $p = 0.001$; experimental manipulation: $F_{1,5} = 48.3$, $p = 0.001$; interaction: $F_{1.3,6.3} = 31.2$, $p = 0.001$). Furthermore, monkeys increased the number of

completed choices per component under saline substitution conditions (**Figure 1B**: choice component: $F_{1.1,5.2} = 154.4$, $p < 0.0001$; experimental manipulation: $F_{1,5} = 93.1$, $p = 0.0002$; interaction: $F_{1.1,5.2} = 154.4$, $p < 0.0001$).

3.2 Effect of naltrexone on heroin choice

Figure 2 shows the average of the last three days of 7-day continuous naltrexone treatment (0.0032-0.032 mg/kg/h) on heroin-vs.-food choice. Naltrexone dose-dependently decreased heroin choices and reciprocally increased food choices (**Figure 2A**: heroin dose: $F_{2.4,12} = 79.6$, $p < 0.0001$; naltrexone dose: $F_{1.5,7.6} = 10.8$, $p = 0.008$; interaction: $F_{2.6,13.2} = 4.8$, $p = 0.02$). In addition, naltrexone treatment increased the number of choices completed per component (**Figure 2C**: heroin dose: $F_{1.1,5.2} = 154.4$, $p < 0.0001$; naltrexone dose: $F_{1,5} = 93.1$, $p = 0.0002$; interaction: $F_{1.1,5.2} = 154.4$, $p < 0.0001$). All three naltrexone doses significantly increased total session choices and 0.032 mg/kg/h naltrexone significantly increased total food choices and decreased total heroin choices (**Figure 2B**: dependent measure: $F_{1,5.1} = 144.5$, $p < 0.0001$; naltrexone dose: $F_{1.3,6.7} = 18.8$, $p = 0.0028$; interaction: $F_{1.6,7.8} = 8.8$, $p = 0.0125$). As shown in **Figure 2D**, seven days of 0.032 mg/kg/h naltrexone treatment resulted in plasma naltrexone concentrations of approximately 20 ng/ml. Notably, the initiation of naltrexone treatment did not precipitate somatic withdrawal signs (e.g., diarrhea) in any monkey, suggesting an absence of opioid dependence.

3.4 Effect of lorcaserin on heroin choice

Figure 3 shows the average of the last three days of seven days of continuous lorcaserin treatment (0.032-0.32 mg/kg/h) on heroin-vs.-food choice. Lorcaserin (0.32 mg/kg/h) treatment significantly increased heroin-vs.-food choice compared to baseline (**Figure 3A**: heroin dose: $F_{1.6,7.8} = 130.2$, $p < 0.0001$; lorcaserin dose: $F_{2.5,12.6} = 4.7$, $p = 0.02$). Lorcaserin treatment did not significantly alter the number of choices completed per component (**Figure 3C**: heroin dose: $F_{1.1,5.7} = 23.69$, $p < 0.01$) or total session choices, food choices, or heroin choices (**Figure 3B**). However, the highest lorcaserin dose (0.32

mg/kg/h) produced overt signs of sedation (data not shown), and higher lorcaserin doses were not tested due to safety concerns. Across the dose range tested, lorcaserin produced dose-dependent increases in plasma lorcaserin levels, and 7-day 0.32 mg/kg/h lorcaserin treatment resulted in plasma concentrations of approximately 450 ng/ml (**Figure 3D**).

4.0 Discussion

The present study determined the effectiveness of repeated 7-day treatment with the 5-HT_{2C} agonist lorcaserin to attenuate heroin-vs.-food choice in rhesus monkeys. For comparison, 7-day naltrexone treatment and saline substitution for heroin were determined as positive controls. There were three main findings. First, saline substitution for heroin resulted in an attenuation, but not elimination, of responding on the previously heroin-associated key and a reciprocal increase in responding on the food-associated key. Second, 7-day naltrexone treatment significantly decreased heroin choice and produced a reciprocal increase in food choice similar to saline substitution and consistent with the clinical effectiveness of depot naltrexone for OUD. Lastly, 7-day lorcaserin treatment significantly increased heroin-vs.-food choice. Overall, the present results do not support the clinical utility of lorcaserin as a candidate OUD medication.

4.1 Effects of saline substitution and naltrexone treatment

The present study compared the effects of three treatments designed to reduce or eliminate the centrally mediated abuse-related effects of heroin. Specifically, saline substitution prevents heroin delivery to the body as a whole, naltrexone allows heroin delivery and distribution to MORs in brain but prevents MOR binding by heroin and its metabolites, and lorcaserin allows heroin and metabolite delivery, distribution, and MOR binding but is intended to oppose heroin-induced activation of brain reward systems. The first of these approaches, saline substitution, eliminates heroin from the environment and shows the maximum effects that can be achieved with antagonist approaches intended to block heroin effects. The elimination of heroin from the environment is the principal goal of “supply side” anti-drug

interventions ((Greenfield and Paoli, 2017), e.g. policies to prevent the manufacturing and distribution of heroin)), and it is the persistence of heroin availability despite supply-side interventions that necessitates development of effective OUD treatments for vulnerable individuals. Nonetheless, the present results with saline substitution provide evidence to suggest that that blocking heroin effects has the potential to reduce heroin-maintained behavior and promote more adaptive behaviors maintained by non-drug reinforcers.

This desirable outcome of behavioral allocation away from heroin and towards non-drug reinforcers (i.e. food) could also be achieved with appropriate doses of the FDA-approved maintenance medication naltrexone. A naltrexone dose of 0.032 mg/kg/h was necessary to produce a minimal 8-fold potency shift in the heroin-vs.-food choice dose effect function and resulted in plasma naltrexone levels of approximately 20 ng/mL. Plasma naltrexone levels of ≥2 ng/mL in humans following depot naltrexone administration are sufficient to antagonize effects of 25mg IV heroin (Comer et al., 2002; Sullivan et al., 2006). For comparison, oral naltrexone 50 mg results in peak naltrexone levels of approximately 10 ng/mL in humans (Dunbar et al., 2006). The present naltrexone results are consistent with previous acute and continuous naltrexone treatments on opioid-vs.-food choice in rats (Townsend et al., 2019) and monkeys (Maguire et al., 2019), and continuous naloxone treatment effects on heroin-vs.-food choice in monkeys (Negus, 2006). Furthermore, the present results are also consistent with depot naltrexone treatment effects on heroin-vs.-money choice in humans (Comer et al., 2006) and clinical trials examining naltrexone effectiveness (Comer et al., 2006; Krupitsky et al., 2011; Lee et al., 2018). Overall, these naltrexone results provide an empirical framework for interpreting the effectiveness of candidate OUD medications such as lorcaserin.

4.2 Lorcaserin effects on heroin choice

Repeated lorcaserin treatment failed to attenuate heroin-vs.-food choice in monkeys and, in fact, significantly increased heroin-vs.-food choice. Peak lorcaserin plasma levels during the present study were approximately 5-fold larger than peak lorcaserin levels reported in humans after treatment with clinically available formulations used for obesity treatment (Christopher et al., 2016), suggesting that a

sufficient dose range was examined. Moreover, the highest dose tested in the present study produced overt signs of sedation in some monkeys, and higher doses were not tested due to safety concerns. Previous studies in rats (Neelakantan et al., 2017) and nonhuman primates (Kohut and Bergman, 2018; Maguire et al., 2019) found that lorcaserin dose-dependently decreased opioid self-administration and opioid-induced reinstatement of extinguished opioid self-administration after acute treatment. Furthermore, decreases in opioid self-administration were sustained during repeated lorcaserin treatment, and both acute and repeated lorcaserin-treatment effects displayed some degree of behavioral selectivity insofar as opioid self-administration was decreased without a significant decrease in food-maintained responding (Kohut and Bergman, 2018). Although behavioral selectivity to decrease opioid self-administration is a desirable attribute of candidate medications (Banks et al., 2019; Mello and Negus, 1996), the expression of behavioral selectivity can be influenced by experimental variables independent of the candidate medication, and the present results suggest that the degree of behavioral selectivity is not sufficient to provide safe and effective decreases in opioid reinforcement.

One of these experimental variables is the unit heroin dose available during the self-administration session. For example, repeated 1 mg/kg/day lorcaserin decreased rates of 3.2 and 10 μg/kg/injection heroin self-administration, but not food-maintained responding, in rhesus monkeys when assessed under a multi-day progressive-ratio procedure (Kohut and Bergman, 2018). Consistent with these previous results, there was a non-significant trend in the present study for 0.32 mg/kg/h lorcaserin to decrease the number of choices completed per component during 10 μg/kg/injection unit heroin dose availability and during a choice component where heroin-vs.-food choice was 100% under baseline conditions. However, unlike naltrexone treatment effects shown in Figure 2, lorcaserin failed to promote behavioral reallocation away from heroin and towards the alternative non-drug food reinforcer at any unit heroin dose. OUD medications that decrease both large- and small-dose heroin self-administration should be prioritized because OUD typically involves consumption of large drug doses and because behavior

maintained by small drug doses are often sensitive to nonpharmacological strategies such as contingency management or the therapeutic workplace (Jarvis et al., 2017).

Lorcaserin and other 5-HT_{2c} agonists are under consideration as candidate OUD medications based on evidence that they might be effective to oppose and limit abuse-related MOR agonist activation of the mesolimbic DA system. However, the present results suggest that this strategy for functional antagonism of MOR agonist effects is not as effective as saline substitution or receptor antagonism, which prevent MOR agonists from binding and activating MORs in the first place. Rather, these results suggest that sustained 5-HT_{2c} receptor activation may produce both direct effects that pose safety concerns and a basal tone of neural activity that actually increases the relative reinforcing efficacy of MOR agonists in comparison to food as a non-drug alternative reinforcer.

4.3 Conclusions

In conclusion, the present lorcaserin treatment effects on heroin-vs.-food choice parallel differences in lorcaserin treatment effects on cocaine self-administration based on the schedule of reinforcement. For example, repeated lorcaserin treatment decreased rates of cocaine self-administration under fixed-ratio and progressive-ratio schedules of reinforcement (Collins et al., 2016; Gerak et al., 2016), but failed to attenuate cocaine-vs.-food choice under a concurrent schedule of reinforcement (Banks and Negus, 2016) in rhesus monkeys (for review, see (Collins et al., 2017)). Recently, lorcaserin failed to attenuate cocaine-vs.-money choice and enhanced subjective effects of cocaine in humans (Pirtle et al., 2019). Although there are currently no published human laboratory studies or clinical trials examining lorcaserin treatment effects opioid-taking behavior, results from an unpublished human laboratory study found lorcaserin maintenance also failed to attenuate oxycodone-vs.-money choice (Comer, personal communication). Consistent with the present results, these human laboratory results provide further evidence against the clinical utility of lorcaserin as a candidate OUD medication. Moreover, the present results further highlight the utility of preclinical drug-vs.-food choice procedures to

efficiently evaluate candidate OUD medications to prioritize novel therapeutics for promotion to human laboratory drug self-administration studies and clinical trials (Banks et al., 2019).

References

Banks, M.L., 2017. Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder. Annals of the New York Academy of Sciences 1394(1), 92-105.

Banks, M.L., Blough, B.E., 2015. Effects of environmental maniuplations and bupropion and risperidone treatments on choice between methamphetamine and food in rhesus monkeys. Neuropsychoharmacology 40, 2198-2206.

Banks, M.L., Blough, B.E., Negus, S.S., 2011. Effects of monoamine releasers with varying selectivity for releasing dopamine/norepinephrine versus serotonin on choice between cocaine and food in rhesus monkeys. Behavioural pharmacology 22(8), 824-836.

Banks, M.L., Hutsell, B.A., Blough, B.E., Poklis, J.L., Negus, S.S., 2015. Preclinical Assessment of Lisdexamfetamine as an Agonist Medication Candidate for Cocaine Addiction: Effects in Rhesus Monkeys Trained to Discriminate Cocaine or to Self-Administer Cocaine in a Cocaine Versus Food Choice Procedure. Int J Neuropsychopharmacol.

Banks, M.L., Negus, S.S., 2016. Repeated 7-Day Treatment with the 5-HT2C Agonist Lorcaserin or the 5-HT2A Antagonist Pimavanserin Alone or in Combination Fails to Reduce Cocaine vs Food Choice in Male Rhesus Monkeys. Neuropsychopharmacology 42, 1082.

Banks, M.L., Negus, S.S., 2017. Insights from Preclinical Choice Models on Treating Drug Addiction. Trends Pharmacol Sci 38, 181-194.

Banks, M.L., Townsend, E.A., Negus, S.S., 2019. Testing the 10 most wanted: a preclinical algorithm to screen candidate opioid use disorder medications. Neuropsychopharmacology.

Blanco, C., Iza, M., Schwartz, R.P., Rafful, C., Wang, S., Olfson, M., 2013. Probability and predictors of treatment-seeking for prescription opioid use disorders: A National Study. Drug and Alcohol Dependence 131(1), 143-148.

Blanco, C., Volkow, N.D., 2019. Management of opioid use disorder in the USA: present status and future directions. The Lancet 393(10182), 1760-1772.

Christopher, R., Morgan, M., Ferry, J., Rege, B., Tang, Y., Kristensen, A., Shanahan, W., 2016. Single- and Multiple-dose Pharmacokinetics of a Lorcaserin Extended-release Tablet. Clinical Therapeutics 38(10), 2227-2238.e2224.

Collins, F.S., Koroshetz, W.J., Volkow, N.D., 2018. Helping to End Addiction Over the Long-term: The Research Plan for the NIH HEAL InitiativeNIH Helping to End Addiction Over the Long-term InitiativeNIH Helping to End Addiction Over the Long-term Initiative. JAMA 320(2), 129-130.

Collins, G.T., Gerak, L.R., France, C.P., 2017. The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders. Neuropharmacology.

Collins, G.T., Gerak, L.R., Javors, M.A., France, C.P., 2016. Lorcaserin Reduces the Discriminative Stimulus and Reinforcing Effects of Cocaine in Rhesus Monkeys. J Pharmacol Exp Ther 356(1), 85-95.

Comer, S.D., Collins, E.D., Kleber, H.D., Nuwayser, E.S., Kerrigan, J.H., Fischman, M.W., 2002. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology 159(4), 351-360.

Comer, S.D., Sullivan, M.A., Yu, E., et al., 2006. Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Arch Gen Psychiatry 63(2), 210-218.

Dunbar, J.L., Turncliff, R.Z., Dong, Q., Silverman, B.L., Ehrich, E.W., Lasseter, K.C., 2006. Single- and Multiple-Dose Pharmacokinetics of Long-acting Injectable Naltrexone. Alcoholism: Clinical and Experimental Research 30(3), 480-490.

Gerak, L.R., Collins, G.T., France, C.P., 2016. Effects of lorcaserin on cocaine and methamphetamine self-administration and reinstatement of extinguished responding in rhesus monkeys. J Pharmacol Exp Ther.

Greenfield, V.A., Paoli, L., 2017. Research as due diligence: What can supply-side interventions accomplish and at what cost? International Journal of Drug Policy 41, 162-163.

Griffiths, R.R., Wurster, R.M., Brady, J.W., 1976. Discrete-trial choice procedure: effects of naloxone and methadone on choice between food and heroin. Pharmacol Rev 27: 357-365.

Han, B., Compton, W.M., Blanco, C., Jones, C.M., 2018. Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults. Annals of Internal Medicine 168(5), 383-384.

Hart, C.L., Haney, M., Foltin R.W., Fischman M.W., 2000. Alternative reinforcers differentially modify cocaine self-administration by humans. Behav Pharmacol 11: 87-91.

Jarvis, B.P., Holtyn, A.F., DeFulio, A., Dunn, K.E., Everly, J.J., Leoutsakos, J.-M.S., Umbricht, A., Fingerhood, M., Bigelow, G.E., Silverman, K., 2017. Effects of incentives for naltrexone adherence on opiate abstinence in heroin-dependent adults. Addiction 112(5), 830-837.

Johanson, C.E., 1976. Pharmacological and environmental variables affecting drug preference in rhesus monkeys. Pharmacol Revs 27: 343-355.

Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3(8):760-73.

Kohut, S.J., Bergman, J., 2018. Lorcaserin decreases the reinforcing effects of heroin, but not food, in rhesus monkeys. European Journal of Pharmacology 840, 28-32.

Krupitsky, E., Nunes, E.V., Ling, W., Illeperuma, A., Gastfriend, D.R., Silverman, B.L., 2011. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. The Lancet 377(9776), 1506-1513.

Lee, J.D., Nunes, E.V., Novo, P., Bachrach, K., Bailey, G.L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C.C., King, J., Lindblad, R., Liu, D., Matthews, A.G., May, J., Peavy, K.M., Ross, S., Salazar, D., Schkolnik, P., Shmueli-Blumberg, D., Stablein, D., Subramaniam, G., Rotrosen, J., 2018. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. The Lancet 391(10118), 309-318.

Maguire, D.R., Gerak, L.R., Woods, J.H., Husbands, S.M., Disney, A., France, C.P., 2019. Long-Lasting Effects of Methocinnamox on Opioid Self-Administration in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics 368(1), 88-99.

Mello, N.K., Negus, S.S., 1996. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 14(6), 375-424.

Neelakantan, H., Holliday, E.D., Fox, R.G., Stutz, S.J., Comer, S.D., Haney, M., Anastasio, N.C., Moeller, F.G., Cunningham, K.A., 2017. Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats. ACS Chemical Neuroscience 8(5), 1065-1073.

Negus, S.S., 2006. Choice between Heroin and Food in Nondependent and Heroin-Dependent Rhesus Monkeys: Effects of Naloxone, Buprenorphine, and Methadone. J Pharmacol Exp Ther 317(2), 711-723.

Negus, S.S., Banks, M.L., 2013. Medications Development for Opioid Abuse, in: Pierce, R.C., Kenny, P.J. (Eds.), Addiction. Cold Springs Harbor, New Yrok.

Pirtle, J.L., Hickman, M.D., Boinpelly, V.C., Surineni, K., Thakur, H.K., Grasing, K.W., 2019. The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study. Pharmacology Biochemistry and Behavior 180, 52-59.

Rasmussen, K., White, D.A., Acri, J.B., 2019. NIDA's medication development priorities in response to the Opioid Crisis: ten most wanted. Neuropsychopharmacology 44(4), 657-659.

Sullivan, M.A., Vosburg, S.K., Comer, S.D., 2006. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology 189(1), 37-46.

Tanum, L., Solli, K., Latif, Z., et al., 2017. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial. JAMA Psychiatry 74(12), 1197-1205.

Townsend, E.A., Blake, S., Faunce, K.E., Hwang, C.S., Natori, Y., Zhou, B., Bremer, P.T., Janda, K.D., Banks, M.L., 2019. Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats. Neuropsychopharmacology.

Volkow, N.D., Collins, F.S., 2017. The Role of Science in Addressing the Opioid Crisis. New England Journal of Medicine 377(4), 391-394.

Volkow, N.D., Frieden, T.R., Hyde, P.S., Cha, S.S., 2014. Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic. New England Journal of Medicine 370(22), 2063-2066.

Willins, D.L., Meltzer, H.Y., 1998. Serotonin 5-HT2C agonists selectively inhibit morphine-induced dopamine efflux in the nucleus accumbens. Brain Research 781(1), 291-299.

Woolverton, W.L., Balster, R.L., 1979. Effects of lithium on choice between cocaine and food in the rhesus monkey. Commun Psychopharmacol 3: 309-318.

Figure Captions

Figure 1. Effects of 7-day saline substitution on choice between heroin and food in female rhesus monkeys (*n*=6). Top and bottom abscissae: unit dose of heroin in milligrams per kilogram per injection or heroin-associated stimuli. Top ordinate (A): percent choice of heroin or heroin-associated stimuli. Bottom ordinate (B): number of choices completed per component. Points represent mean ±SEM obtained during days 5-7 of each 7-day treatment period. Filled symbols denote significantly different from baseline ($p<0.05$).

Figure 2. Effects of 7-day intravenous naltrexone (0.0032-0.032 mg/kg/h) treatment on choice between heroin and food in female rhesus monkeys (*n*=6). Left abscissae: unit dose of heroin in milligrams per kilogram per injection. Top left ordinate (A): percent heroin choice. Bottom left ordinate (C): number of choices completed per component. Top right abscissae: dependent measure. Top right ordinate (B): number of choices made per session. Bottom right abscissae: dose of naltrexone (mg/kg/h). Bottom right ordinate (D): plasma naltrexone concentration (ng/ml). Points and bars of A, B, and C represent mean ±SEM obtained during days 5-7 of each 7-day treatment period. Bars of D represent mean ±SEM. Filled symbols in the left panels or * in the top right panel denote significantly different from baseline ($p<0.05$).

Figure 3. Effects of 7-day intravenous lorcaserin (0.032-0.32 mg/kg/h) treatment on choice between heroin and food in male (*n*=1) and female (*n*=5) rhesus monkeys. Left abscissae: unit dose of heroin in milligrams per kilogram per injection. Top left ordinate (A): percent heroin choice. Bottom left ordinate (C): number of choices completed per component. Top right abscissae: dependent measure. Top right ordinate (B): number of choices made per session. Bottom right abscissae: dose of lorcaserin (mg/kg/h). Bottom right ordinate (D): plasma concentration (ng/ml) of lorcaserin. Points and bars of A, B, and C represent mean ±SEM obtained during days 5-7 of each 7-day treatment period. Bars of D represent mean ±SEM. Numbers in parentheses indicate the number of monkeys contributing to that data point if fewer

than the total sample size (n=6). * denotes collapsed 0.32 mg/kg/h lorcaserin-treatment data are significantly (p<0.05) different from saline.

Role of funding source

Research was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Numbers UH3DA041146, T32DA007027, P30DA033934, and F32DA047026. The National Institute on Drug Abuse had no role in study design, collection, analysis or interpretation of the data, in the writing or decision to submit the manuscript for publication. The manuscript content is solely the responsibility of the authors and does not necessarily reflect the official views of the National Institutes of Health.

Contributors

EAT, SSN, and MLB were responsible for study concept, design, and execution. EAT and MLB drafted the initial manuscript. All authors critically reviewed the manuscript for content and approved the final manuscript version submitted for publication. We appreciate the technical assistance of Jennifer Gough, Kaycee Faunce, and Rebekah Tenney. We also acknowledge Kevin Costa for writing the original version of the behavioral program that was modified for the choice studies conducted in this manuscript.

Conflict of Interest

All authors declare there are no competing financial interests or potential conflicts of interest in relation to the research described.


Baseline
No Heroin
A
% Heroin Choice or Heroin-associated Stimuli
100
75
50
25
0
0
0.001
0.0032
0.01
0.032
B
Choices / Component
10
8
6
4
2
0
0
0.001
0.0032
0.01
0.032
Unit Dose Heroin (mg/kg/inj) or Heroin-associated Stimuli


Naltrexone (mg/kg/h)
+ Saline
+ 0.01
+ 0.0032
+ 0.032
A
% Heroin Choice
100
75
50
25
0
0
0.001
0.0032
0.01
0.032
Baseline
+ 0.0032 mg/kg/h Naltrexone
+ 0.01 mg/kg/h Naltrexone
+ 0.032 mg/kg/h Naltrexone
B
Choices per Session
50
40
30
20
10
0
Total
Food
Heroin
C
Choices / Component
10
8
6
4
2
0
0
0.001
0.0032
0.01
0.032
Unit Dose Heroin (mg/kg/inj)
D
Plasma Concentration (ng/ml)
40
30
20
10
0
0.0032
0.01
0.032
Naltrexone (mg/kg/h)


Lorcaserin (mg/kg/h)
+ Saline
+ 0.1
+ 0.032 (5)
+ 0.32 (4)
Baseline
+ 0.032 mg/kg/h Lorcaserin (5)
+ 0.1 mg/kg/h Lorcaserin
+ 0.32 mg/kg/h Lorcaserin (4)
A
*
% Heroin Choice
100
75
50
25
0
0
0.001
0.0032
0.01
0.032
B
Choices per Session
50
40
30
20
10
0
Total
Food
Heroin
C
Choices /Component
10
8
6
4
2
0
0
0.001
0.0032
0.01
0.032
Unit Dose Heroin (mg/kg/inj)
D
Plasma Concentration (ng/ml)
800
600
400
200
0
(5)
(3)
0.032
0.1
0.32
Lorcaserin (mg/kg/h)